Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryBCBST Tennessee MS Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    DraftBlueCross BlueShield of TennesseePolicy ID_CHS_71362025_1026

    Multiple Sclerosis Products: Ocrevus, Ocrevus Zunovo, and Briumvi

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_71362025_1026 alerts

    Get alerted when Policy ID_CHS_71362025_1026 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and authorization criteria for Briumvi, Ocrevus, and Ocrevus Zunovo for multiple sclerosis indications in Tennessee, including clinical criteria, prescriber requirements, dosing limits, and nonconcomitant-use conditions.

    Policy Summary
    PayerBlueCross BlueShield of Tennessee
    PolicyMultiple Sclerosis Products: Ocrevus, Ocrevus Zunovo, and Briumvi
    Policy CodePolicy ID_CHS_71362025_1026
    Change TypeNo material change
    Effective DateDec 31, 202644d
    Next Review DateN/A
    Key ActionObtain prior authorization for covered multiple sclerosis indications; initial and continuation authorizations may be granted for 12 months when criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Products addressed
    12 monthsAuthorization duration
    3Relapsing MS forms covered
    2Primary progressive MS products

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    No
    Concurrent disease-modifying therapy

    Covered Indications and Eligibility

    Relapsing Forms of Multiple Sclerosis (MS)

    Covered when the applicable criterion below is met.

    ALL of the following

    • The member has been diagnosed with a relapsing form of multiple sclerosis, including relapsing-remitting disease or secondary progressive disease with continued relapse.

      Authorization may be granted for 12 months.

    Clinically Isolated Syndrome

    Covered when the following criterion is met.

    ALL of the following

    • The member is being treated for clinically isolated syndrome of multiple sclerosis.

      Authorization may be granted for 12 months.

    Primary Progressive MS (Ocrevus and Ocrevus Zunovo Only)

    Covered when the following criterion is met.

    ALL of the following

    • The member is being treated for primary progressive multiple sclerosis with Ocrevus or Ocrevus Zunovo.

      Authorization may be granted for 12 months.

    Continuation of Therapy

    Covered when the following criterion is met for any indication.

    ALL of the following

    • The member, including a new member, achieves or maintains a positive clinical response while receiving the requested medication, as evidenced by disease stability or improvement.

      Authorization may be granted for 12 months.

    Other Criteria

    Covered when the applicable criterion below is met.

    ALL of the following

    • For products FDA-approved in adults only, the member is younger than 18 years of age and the benefits of treatment outweigh the risks.

    Briumvi is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Ocrevus and Ocrevus Zunovo are indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, and for the treatment of primary progressive MS in adults. All other indications are considered experimental/investigational and not medically necessary.

    The requested medication must not be used concomitantly with other disease-modifying multiple sclerosis agents. Ampyra and Nuedexta are not disease-modifying multiple sclerosis agents.

    Non-FDA-approved indications for Briumvi, Ocrevus, and Ocrevus Zunovo are considered experimental/investigational and not medically necessary.

    Product Dosing and Administration

    Briumvi dosing
    First infusion150 mg once; intravenous
    Second infusion450 mg given 2 weeks after the first infusion; intravenous
    Subsequent infusions450 mg every 24 weeks; intravenous
    Ocrevus adult dosing
    Initial dose300 mg intravenously
    Second doseA second 300 mg infusion 2 weeks after the initial dose
    Maintenance dose600 mg intravenously every 6 months

    Authorization and Documentation Requirements

    Prior Authorization

    12-Month Authorization Required

    Prior authorization is required for 12 months for initial requests and continuation requests when the applicable indication and authorization criteria are met.

    • Relapsing forms of MS, including relapsing-remitting disease and secondary progressive disease with continued relapse: authorization may be granted for 12 months.
    • Clinically isolated syndrome of MS: authorization may be granted for 12 months.
    • Primary progressive MS: authorization may be granted for 12 months for Ocrevus and Ocrevus Zunovo.
    • Continuation requests, including for new members, may be authorized for 12 months when the member achieves or maintains a positive clinical response, evidenced by disease stability or improvement while receiving the requested medication.
    Documentation Required

    Diagnosis and Indication Documentation

    Document the member's diagnosis and the applicable MS disease category supporting the request.

    Policy Scope and Therapy Context

    This policy addresses Briumvi, Ocrevus, and Ocrevus Zunovo for the treatment of multiple sclerosis. Covered disease categories include relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease; primary progressive multiple sclerosis is covered for Ocrevus and Ocrevus Zunovo. Treatment must be prescribed by or provided in consultation with a neurologist, and coverage is subject to the applicable clinical criteria and exclusions.

    Multiple Sclerosis Disease Categories

    Relapsing forms of multiple sclerosis
    Clinically isolated syndromeIncluded among relapsing forms of multiple sclerosis in adults
    Relapsing-remitting diseaseIncluded among relapsing forms of multiple sclerosis in adults
    Active secondary progressive diseaseIncluded among relapsing forms of multiple sclerosis in adults
    Relapsing secondary progressive MS
    Disease typeSecondary progressive multiple sclerosis
    Relapsing classificationIncluded under relapsing forms of multiple sclerosis
    Required feature
    Policy Summary
    PayerBlueCross BlueShield of Tennessee
    PolicyMultiple Sclerosis Products: Ocrevus, Ocrevus Zunovo, and Briumvi
    Policy CodePolicy ID_CHS_71362025_1026
    Change TypeNo material change
    Effective DateDec 31, 202644d
    Next Review DateN/A
    Key ActionObtain prior authorization for covered multiple sclerosis indications; initial and continuation authorizations may be granted for 12 months when criteria are met.
    SourceLink
    On This Page
    Covered Indications and EligibilityProduct Dosing and AdministrationAuthorization and Documentation RequirementsPolicy Scope and Therapy ContextMultiple Sclerosis Disease Categories
    Ocrevus pediatric dosing
    Age rangeMembers 10 to less than 18 years
    Weight at least 35 kgInitial 300 mg followed 2 weeks later by a second 300 mg dose; intravenous
    Weight 10 to less than 35 kgInitial 150 mg followed 2 weeks later by a second 150 mg dose; intravenous
    Maintenance dose600 mg intravenously every 6 months
    Ocrevus Zunovo dosing
    Dose920/23,000 mg-units
    Administration routeSubcutaneous
    Administration intervalEvery 6 months
    • Relapsing forms of multiple sclerosis, including relapsing-remitting disease and active secondary progressive disease in adults; secondary progressive disease must include continued relapse.
    • Clinically isolated syndrome of multiple sclerosis.
    • Primary progressive multiple sclerosis in adults, for Ocrevus or Ocrevus Zunovo only.
    Documentation Required

    Document Continuation Response

    For continuation authorization, document that the member has achieved or maintained a positive clinical response to the requested medication.

    • Positive clinical response must be evidenced by disease stability or improvement while receiving the requested medication.
    • This continuation criterion applies to all indications and includes new members.
    Documentation Required

    Review Concomitant Therapy

    Document that the requested medication will not be used concomitantly with another disease-modifying multiple sclerosis agent.

    • Ampyra and Nuedexta are not disease-modifying therapies and are exceptions to the concomitant-therapy restriction.
    • For products FDA-approved only for adults, pediatric authorization may be considered for members younger than 18 when the benefits outweigh the risks.
    Documentation Required

    Neurologist Involvement Required

    The medication must be prescribed by or in consultation with a neurologist.

    • Identify the prescribing neurologist or consulting neurologist in the authorization documentation.
    Documentation Required

    Support Tennessee Off-Label Use

    For an off-label indication, document that the use is recognized by a statutorily recognized standard reference compendium or supported by published peer-reviewed medical literature, consistent with Tennessee Code Annotated Section 56-7-2352.

    • BlueCross BlueShield of Tennessee's medical policy complies with Tennessee requirements for coverage of off-label indications of FDA-approved drugs.
    Denial Risk

    Unapproved or Noncovered Indication

    All indications other than the specified FDA-approved indications are considered experimental/investigational and not medically necessary.

    • Briumvi is covered for relapsing forms of MS in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
    • Ocrevus and Ocrevus Zunovo are covered for relapsing forms of MS and primary progressive MS in adults.
    • Use outside the approved or covered indications is not covered unless it meets applicable Tennessee off-label coverage requirements.
    Denial Risk

    Concurrent Disease-Modifying Therapy

    Authorization may be denied when the requested medication is used with another disease-modifying multiple sclerosis agent.

    • Ampyra and Nuedexta are not disease-modifying therapies and do not trigger this prohibition.
    Denial Risk

    Neurologist Involvement Required

    The medication must be prescribed by a neurologist or prescribed in consultation with a neurologist.

    • A prescribing or consulting neurologist must be involved in the member's care.
    Denial Risk

    Approval Criteria and Exclusions

    Coverage applies only when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy.

    • Verify the diagnosis and covered indication.
    • Verify the applicable 12-month authorization and continuation-response requirements.
    • Verify that no concomitant disease-modifying MS therapy is being used and that required neurologist involvement is documented.
    The member continues to experience relapse